Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 1,800 shares of the firm’s stock in a transaction that occurred on Thursday, February 16th. The shares were purchased at an average price of $8.65 per share, with a total value of $15,570.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $26,546,426.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, February 15th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were purchased at an average price of $8.46 per share, with a total value of $15,228.00.
  • On Tuesday, February 14th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were purchased at an average price of $8.41 per share, with a total value of $15,138.00.
  • On Monday, February 13th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were purchased at an average price of $8.36 per share, with a total value of $15,048.00.
  • On Friday, February 10th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were purchased at an average price of $8.14 per share, with a total value of $14,652.00.
  • On Thursday, February 9th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The shares were purchased at an average price of $8.07 per share, with a total value of $80,700.00.
  • On Wednesday, February 8th, Phillip Md Et Al Frost acquired 15,600 shares of Opko Health stock. The shares were purchased at an average price of $8.13 per share, with a total value of $126,828.00.
  • On Tuesday, February 7th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The shares were purchased at an average price of $8.27 per share, with a total value of $44,658.00.
  • On Monday, February 6th, Phillip Md Et Al Frost acquired 20,600 shares of Opko Health stock. The shares were purchased at an average price of $8.32 per share, with a total value of $171,392.00.
  • On Thursday, February 2nd, Phillip Md Et Al Frost acquired 6,000 shares of Opko Health stock. The shares were purchased at an average price of $8.53 per share, with a total value of $51,180.00.
  • On Wednesday, February 1st, Phillip Md Et Al Frost acquired 9,000 shares of Opko Health stock. The shares were purchased at an average price of $8.59 per share, with a total value of $77,310.00.

Opko Health, Inc. (NASDAQ:OPK) traded down 0.629% during mid-day trading on Friday, reaching $8.695. The company had a trading volume of 1,144,853 shares. The stock’s market capitalization is $4.85 billion. Opko Health, Inc. has a one year low of $7.99 and a one year high of $12.15. The company’s 50-day moving average is $8.83 and its 200-day moving average is $9.86.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/02/17/insider-buying-opko-health-inc-opk-ceo-buys-1800-shares-of-stock.html

“Insider Buying: Opko Health, Inc. (OPK) CEO Buys 1,800 Shares of Stock” was first published by American Banking News and is the property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/02/17/insider-buying-opko-health-inc-opk-ceo-buys-1800-shares-of-stock.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of OPK. AQR Capital Management LLC purchased a new position in Opko Health during the fourth quarter worth $105,000. Formidable Asset Management LLC increased its position in Opko Health by 10.4% in the fourth quarter. Formidable Asset Management LLC now owns 11,638 shares of the company’s stock worth $108,000 after buying an additional 1,096 shares during the period. Comerica Bank purchased a new position in Opko Health during the fourth quarter worth $117,000. National Planning Corp increased its position in Opko Health by 1.2% in the fourth quarter. National Planning Corp now owns 16,240 shares of the company’s stock worth $138,000 after buying an additional 200 shares during the period. Finally, Envestnet Asset Management Inc. increased its position in Opko Health by 23.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 15,355 shares of the company’s stock worth $142,000 after buying an additional 2,927 shares during the period. 22.58% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the company. TheStreet downgraded Opko Health from a “c-” rating to a “d+” rating in a research note on Wednesday, February 1st. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 18th. Laidlaw reaffirmed a “buy” rating and issued a $19.00 price objective (down from $22.00) on shares of Opko Health in a research report on Tuesday, January 3rd. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $19.50 price objective (down from $20.00) on shares of Opko Health in a research report on Tuesday, January 3rd. Finally, Standpoint Research reaffirmed a “buy” rating on shares of Opko Health in a research report on Friday, December 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. Opko Health has a consensus rating of “Hold” and a consensus target price of $15.21.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.